60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) EV-to-EBIT : 0.00 (As of May. 27, 2024)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 60 Degrees Pharmaceuticals's Enterprise Value is $0.00 Mil. 60 Degrees Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $0.36 Mil. Therefore, 60 Degrees Pharmaceuticals's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for 60 Degrees Pharmaceuticals's EV-to-EBIT or its related term are showing as below:

SXTPW' s EV-to-EBIT Range Over the Past 10 Years
Min: -264.31 Med: -7.44 Max: 30.57
Current: 30.57

During the past 4 years, the highest EV-to-EBIT of 60 Degrees Pharmaceuticals was 30.57. The lowest was -264.31. And the median was -7.44.

SXTPW's EV-to-EBIT is ranked worse than
77.83% of 424 companies
in the Biotechnology industry
Industry Median: 10 vs SXTPW: 30.57

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. 60 Degrees Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil. 60 Degrees Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $0.36 Mil. 60 Degrees Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was %.

60 Degrees Pharmaceuticals EV-to-EBIT Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals EV-to-EBIT Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

-9.00

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial							-	-	-241.63	-9.00	28.26

Competitive Comparison of 60 Degrees Pharmaceuticals's EV-to-EBIT

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's EV-to-EBIT falls into.

60 Degrees Pharmaceuticals EV-to-EBIT Calculation

60 Degrees Pharmaceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	0.000	/	0.358
	=	0.00

60 Degrees Pharmaceuticals's current Enterprise Value is $0.00 Mil.
60 Degrees Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36 Mil.

60 Degrees Pharmaceuticals (NAS:SXTPW) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

60 Degrees Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	0.358	/	0
	=	%

60 Degrees Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $0.00 Mil.
60 Degrees Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.36 Mil.

60 Degrees Pharmaceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTPW) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

SXTP:USA

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.